terapia antitrombotica nella sca in pazienti con fa...
TRANSCRIPT
![Page 1: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/1.jpg)
TERAPIAANTITROMBOTICANELLASCAINPAZIENTICONFACRONICA
Dr.ssaPatriziaNoussanOspedaleSanGiovanniBosco
Torino
CardioAlessandria12-13giugno2015
![Page 2: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/2.jpg)
FApermanenteeSCAunaassociazionepericolosa…..
• PrevalenzadiFA1-2%• L’80%deipazien;inFAhaindicazioneaOAC• Il30%deipazien;inFAhaunaconcomitantepatologiavascolareenel20%andràincontroaPTCAconimpiantodistent
InEuropa1-2milionidipazienKinOACpotrebberoavereindicazioneaunaPTCAconstenKng
![Page 3: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/3.jpg)
ReccomendaKonforanKthromboKctherapyinACS-NSTEeSTEMIpaKentsundergoingPCI
![Page 4: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/4.jpg)
Primaryendpoint:firstoccurrenceofstroke,non-CNSsystemicembolus,AMIovasculardeath
![Page 5: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/5.jpg)
(JAmCollCardiol2008;51:818–25)
Kaplan-MeierSurvivalCurvesinRelaKontoAnKcoagulaKonUseatDischarge
![Page 6: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/6.jpg)
RiskofBleedingWithSingle,Dual,orTripleTherapyWithWarfarin,Aspirin,andClopidogrelinPaKentsWithAtrialFibrillaKon
Arch Intern Med. 2010;170(16):1433-1441. !
![Page 7: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/7.jpg)
TRIPLETHERAPY(TT)ASA+P2Y12I+OAC(VKA/NOACS)
4-16%rischiodisanguinamen;
BleedingcomplicaKons ThromboKccomplicaKonsStroke–stentthrombosis
DUALTHERAPYOAC+SINGLEANTIPLATELET
50%isanguinamenK
![Page 8: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/8.jpg)
2010
![Page 9: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/9.jpg)
![Page 10: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/10.jpg)
StudyDesign1:1Randomisa5on:Doubletherapygroup:OAC+75mgClopidogrelqd1monthminimumaSerBMS1yearaSerDES
TripletherapygroupOAC+75mgClopidogrelqd+80mgAspirinqd1monthminimumaSerBMS1yearaSerDES
Followup:1yearPrimaryEndpoint:Theoccurenceofallbleedingevents(TIMIcriteria)SecondaryEndpoints:- CombinaKonofstroke,death,myocardialinfarcKon,stentthrombosisandtargetvesselrevascularisaKon-Allindividualcomponentsofprimaryandsecondaryendpoints
TheWOESTTrial:FirstrandomisedtrialcomparingtworegimenswithandwithoutaspirininpaKentsonoralanKcoagulanttherapy
undergoingcoronarystenKng
![Page 11: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/11.jpg)
|
PrimaryEndpoint:TotalnumberofTIMIbleedingevents
Days
Cumula;
veincide
nceofbleed
ing
0 30 60 90 120 180 270 365
0%
10%
20%
30%
40%
50%
284 210 194 186 181 173 159 140natrisk:279 253 244 241 241 236 226 208
TripletherapygroupDoubletherapygroup 44.9%
19.5%
p<0.001HR=0.3695%CI[0.26-0.50]
![Page 12: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/12.jpg)
PrimaryEndpoint:BleedingeventsTIMIclassifica;on
05
101520253035404550
TIMIMinimal
TIMI Minor TIMI Major Any TIMIbleeding
Doubletherapygroup
Tripletherapygroup
6.5
16.7
11.2
27.2
3.35.8
19.5
44.9%
p<0.001
p<0.001
p<0.001
p=0.159
WOEST
![Page 13: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/13.jpg)
|
Conclusions1. FirstrandomizedtrialtoaddresstheopKmalanKplatelettherapyinpaKentsonOAC
undergoingcoronarystenKng
2. Inthisstudywhichwasspecificallydesignedtodetectbleedingevents,thebleedingratewashigherthanexpected
3. Primaryendpointwasmet:OACplusclopidogrelcauseslessbleedingthantripleanKthromboKctherapy,butnowshowninarandomizedway
4. Secondaryendpointwasmet:withdoubletherapythereisnoexcessofthromboKc/thromboembolicevents:stroke,stentthrombosis,targetvesselrevascularisaKon,myocardialinfarcKonordeath
5. Lessall-causemortalitywithdoubletherapy
LimiK:Numerositàdelcampione(576pts)-69%deipazienKerainOACperFA–accesso
femoralenel74%-PCIelejvanel70-75%-usononrouKnariodiPPI-TTper12mesi
![Page 14: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/14.jpg)
JACCVol.62,2013;62:981–989
![Page 15: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/15.jpg)
InreallifeAFpaKentswithindicaKonsformulKpleanKthromboKcdrugsakerMI/PCI,OACandclopidogrelwasequalorbemeronbothbenefitandsafeyoutcomes
comparedtotripletherapy
![Page 16: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/16.jpg)
![Page 17: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/17.jpg)
STEMIpaKents
![Page 18: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/18.jpg)
ACS-NSTEpaKents
Ø PrincipalsaspectsoftheESCguidelinesareconsideredintherespondingcentresØ UncertaintyintheissueofopKmalcomposiKonandduraKonofmulKpleanKthromboKctreatmentandtheopKmalregimen(s)ofNOACSintreatmentstrategies
![Page 19: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/19.jpg)
2014
![Page 20: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/20.jpg)
ToevaluatewethershorteningtheduraKonofclopidogreltherapyfrom6monthsto6weeksakerDESimplantaKonwasassociatedwithasuperiornetclinicaloutcomeinpaKentsreceivingconcomitantaspirinandOAC
ThestudywilltestthehypotesisthatDAPTcomparedwithTTwithnonvalvularAFatlowtomoderateriskofstrokeCHADS2<2akerPCISreducestheriskofbleedingandisnotinferiortoTTforprevenKngthromboemboliccomplicaKons
![Page 21: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/21.jpg)
PrimaryEndpoint:acompositeofDeath,MI,defST,strokeorTIMImajorbleedingat9months
![Page 22: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/22.jpg)
NOACs• IlruolodeiNOACsneipazien;conFAeACSnonè
statovalutatodireeamentemaderivasopraeueodaanalisipost-hocodaRCTssull’u;lizzodeiNOACsinassociazioneallaterapiaan;aggreganteneipazien;ACS-PCI
• Quandosiu;lizzaunNOACinassociazioneaclopidogrelobassadosediASA,ladosediNOACdau;lizzareèlapiùbassatestataneglistudidiprevenzionedellostrokenellaFA
• Unarecentemetanalisinonhaevidenziatodifferenzenell’incidenzadiIMAtraNOACseWarfarin
• NOACstrialincorso:PIONEERAF-PCIRE-DUALPCI
![Page 23: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/23.jpg)
Conclusions:RatesofthromboKcandbleedingeventsweresimilarinpaKentswithTTandpaKentswithTicagrelorandwarfarin
![Page 24: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/24.jpg)
![Page 25: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/25.jpg)
ConsensusrecommendaKon• Nei pazien; con FA non valvolare u;lizzare gli score di rischio
CHA2DS2-VASC eHas-BLED eGRACERisk per la stra;ficazione delrischioACS
• Se OAC è VKA à TTR>70% con INR 2-2.5 se in associazione aclopidogrele/oASA(75-100mg)(IIa,C)
• SE OAC è NOAC , deve essere u;lizzata la posologia più bassadisponibile ma risultata efficace nella prevenzione dello strokeàDabigatran 110 b.i.d Rivaroxaban 15mg o.d. Apixaban 2.5mg b.i.d.(IIb,C)
• Neipazien;conFAnonvalvolareecoronaropa;astabile>12mesimantenere VKA o NOAC (IIa, B). In casi seleziona;(PTCA di Tc, IVAprossimale , biforcazioni, IMA ricorren; ) si può considerare unprolungamentodelladupliceterapia(IIb,B)
• Accessoradiale,“newgenera;on“DESvsBMS• NOPrasugreleTicagrelornellaTT(III,C)
![Page 26: TERAPIA ANTITROMBOTICA NELLA SCA IN PAZIENTI CON FA …cardioalessandria.it/w/wp-content/themes/seos-business/PDF/2015/... · 3. Primary endpoint was met: OAC plus clopidogrel causes](https://reader036.vdocuments.pub/reader036/viewer/2022070901/5f4d3f00ca80eb34f943b937/html5/thumbnails/26.jpg)